Abstract:Increased neural activity characterizes early Alzheimers disease (AD), serving as a prognostic indicator for disease progression and cognitive decline. Mechanisms that drive this hyperactivity and their behavioral effects remain mostly unrevealed, although normalizing altered excitability levels has been shown to reverse cognitive impairment in early AD, both in animals and humans. Soluble amyloid-β oligomers (oAβ) primary accumulate in limbic regions like hippocampus and induce neuronal hyperexcitability and subsequent cognitive deficits by impairing ion channel s function. Indeed, G protein-gated inwardly rectifying K+ (GIRK) channels -that control neuronal excitability- are greatly affected and their selective pharmacological activation has already been shown very effective to counteract oAβ-induced hyperexcitability and hippocampal dysfunction. However, GIRK gain-of-function in healthy animals disrupts learning, memory and underlying synaptic plasticity, greatly limiting its therapeutic potential in preclinical asymptomatic early AD patients. Therefore, GIRK-based pharmacological treatment needs further investigation to overcome these limitations. Here we tested two doses of a novel, more potent, and neuronal selective GIRK activator, VU0810464, in healthy and early oAB-generated AD male and female mice. Both doses normalized hippocampal synaptic plasticity (long-term potentiation, LTP) and associated spatial object location memory (OLM) without sex dimorphism in AD animals. However, in healthy mice, low VU0810464 dose did not significantly alter LTP and OLM, whereas the high dose disrupted both. Our results suggest that the precise tuning of neural excitability with low dosing of VU0810464 might be a promising strategy to safely treat and prevent hippocampal overexcitation and upstreaming memory deficits in early preclinical asymptomatic phases of AD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the neuronal hyperexcitability caused by soluble amyloid - β oligomers (oAβ) in the early stage of Alzheimer's disease (AD) and the resulting cognitive impairment. Specifically, the paper explores the possibility of restoring normal neuronal excitability and improving cognitive function by regulating the activity of G - protein - gated inward - rectifier potassium channels (GIRK). ### Specific background and objectives of the problem 1. **Relationship between neuronal hyperexcitability and AD**: - In the early stage of AD, neurons show abnormally high activity, which is considered as a predictive indicator of disease progression and cognitive decline. - Soluble amyloid - β oligomers (oAβ) mainly accumulate in limbic regions such as the hippocampus, induce neuronal hyperexcitability and lead to cognitive deficits, and the mechanism involves impairment of ion channel function. 2. **Role of GIRK channels**: - GIRK channels control the excitability of neurons, and their selective pharmacological activation has been proven to effectively counteract oAβ - induced hyperexcitability and hippocampal dysfunction. - However, in healthy animals, gain - of - function of GIRK channels can disrupt learning, memory and related synaptic plasticity, limiting their therapeutic potential in preclinical asymptomatic early - stage AD patients. 3. **Research objectives**: - Explore the effects of a new and more effective GIRK channel activator, VU0810464, at different doses on healthy and early - stage AD model mice. - Determine whether a low dose of VU0810464 can restore synaptic plasticity and spatial object - location memory (OLM) in AD model mice without causing side effects, while not affecting the normal function of healthy mice. ### Overview of research methods - **Animal models**: Non - transgenic male and female mice were used to generate an early - stage AD model by a single intracerebroventricular injection of oAβ. - **Drug treatment**: The effects of two doses (high - dose and low - dose) of VU0810464 on hippocampal long - term potentiation (LTP) and dorsal hippocampus - dependent memory processes were tested. - **Behavioral assessment**: Including object - location memory (OLM) tasks and elevated plus - maze (EPM) tests. - **Electrophysiological recording**: Field excitatory postsynaptic potential (fEPSP) recordings were performed to assess synaptic plasticity. ### Conclusions The research results show that a low dose of VU0810464 can restore synaptic plasticity and related spatial memory functions in AD model mice without significantly changing LTP and OLM in healthy mice. Therefore, a low - dose strategy for precisely adjusting neuronal excitability may be a safe and effective method for treating and preventing early - stage AD. ### Formula representation The formula mainly involved in the paper is for calculating the discrimination index (DI), which is used to evaluate performance in memory tasks: \[ \text{DI} = \frac{\text{Time of exploring the moved object}-\text{Time of exploring the unmoved object}}{\text{Total exploration time}} \] This formula is used for quantitative analysis of the performance of animals in object - location memory tasks.

Low dose of a non-urea selective GIRK channel activator improves hippocampal-dependent synaptic plasticity and memory disrupted by amyloid-β oligomers

Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

Amyloid-β oligomers trigger sex-dependent inhibition of GIRK channel activity in hippocampal neurons in mice

Social and Contextual Memory Impairments Induced by Amyloid-β Oligomers are Rescued by Sigma-1 Receptor Activation

A therapeutic small molecule enhances γ-oscillations and improves cognition/memory in Alzheimer's disease model mice

Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Neuroprotective Effect of Optogenetics Varies With Distance From Channelrhodopsin-2 Expression in an Amyloid--Injected Mouse Model of Alzheimer's Disease

Driving GABAergic neurons optogenetically improves learning, reduces amyloid load and enhances autophagy in a mouse model of Alzheimer's disease

Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model

TrpV1 receptor activation rescues neuronal function and network gamma oscillations from Aβ-induced impairment in mouse hippocampus in vitro

Blockade of adenosine A2A receptors reverses early spatial memory defects in the APP/PS1 mouse model of Alzheimer's disease by promoting synaptic plasticity of adult-born granule cells

Chronic potentiation of metabotropic glutamate receptor 2 with a nanobody accelerates amyloidogenesis in Alzheimer’s disease

GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment.

A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice

Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

Riluzole ameliorates soluble Aβ1–42-induced impairments in spatial memory by modulating the glutamatergic/GABAergic balance in the dentate gyrus

Lamotrigine Attenuates Deficits in Synaptic Plasticity and Accumulation of Amyloid Plaques in App/Ps1 Transgenic Mice

Hippocampal Overexpression of SGK1 Ameliorates Spatial Memory, Rescues Aβ Pathology and Actin Cytoskeleton Polymerization in Middle-Aged APP/PS1 Mice.